PRO 140 (525 mg)

Drug identity checked against registry records

Also recorded as Leronlimab

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionNCT02859961CytoDyn, Inc.Phase 2, Phase 3Completed2020-09-16Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.